X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Liverpool-based Redx Pharma secures ‘transformational’ deal with drugs giant AstraZeneca

Yuvraj_pawp by Yuvraj_pawp
3rd September 2014
in Europe, News

Liverpool biotech firm Redx Pharma has signed a “transformational” multi-million pound deal with global pharmaceutical giant AstraZeneca to develop new drugs that will stop the growth of cancerous tumours.

The research project will see scientists from both companies collaborate to discover and develop new molecules targeting a genetic driver of tumour growth and survival.

Most of the research will be carried out at the Redx laboratories in Liverpool city centre.

Redx will receive an upfront payment with the potential to earn significant further royalties according to the success of the project.

Neither side is prepared to talk figures but, typically, drug development deals with major pharmaceutical companies can be worth hundreds of millions of pounds.

Neil Murray, chief executive at Redx Pharma, told ECHO Business: “We have entered into other collaborations but this deal is transformational for Redx. It is the first one we have done with a blue-chip pharmaceutical company.

“The capability we have established at Redx is fundamental to this deal. AstraZeneca have already done some work on this and we will also be bringing things to the table, too.”

Some of the research work will also be carried out at the BioHub at Alderley Park in Cheshire, set up by AstraZeneca in 2013 to allow life sciences companies to benefit from its expertise, and where Redx was one of the first tenants.

The research collaboration will involve Redx scientists working with AstraZeneca’s Oncology Innovative Medicines group to combine complementary skills to accelerate the drug discovery process.

Redx, which employs around 150 people, will use its early stage drug discovery capabilities to identify novel leads whose further development will be supported by AstraZeneca’s extensive knowledge of the area and strong oncology expertise.

The research will complement AstraZeneca’s strategic approach of targeting genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.

Susan Galbraith, head of the Oncology Innovative Medicines Unit at AstraZeneca, added: “This agreement supports our strategic objectives of accelerating discovery and improving the quality and choice of candidate compounds for our early pipeline.”

Tags: Europe
Previous Post

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®

Next Post

ViiV Healthcare’s Triumeq for HIV treatment receives EU marketing authorisation

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

ViiV Healthcare’s Triumeq for HIV treatment receives EU marketing authorisation

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In